Project Title: Ph I Measles OV MV-NIS for recurrent Medullo/ATRT
Investigators: Sabine Mueller, MD, PhD, MAS
Institutions: UCSF Helen Diller Cancer Center, PNOC Consortium
Study Type: Two arm Phase I clinical trial
For children with recurrent medulloblastoma or AT/RT, outcomes remain poor. Preclinical studies have shown that treatment with modified, attenuated measles virus (MV-NIS) leads to prolonged survival in models of recurrent medulloblastoma and ATRT. Safety studies have demonstrated that MV-NIS has an excellent safety profile and ongoing adult studies are currently testing MV-NIS in adult glioblastoma, ovarian cancer, and multiple myeloma.
MV-NIS is thought to work by attaching and fusing to tumor cell membranes. It binds to CD46, a protein that is overexpressed on the surface of many cancer cell types. After fusing to the tumor cells, MV-NIS may induce cell death.
This Phase I clinical trial will evaluate the safety and efficacy of MV-NIS, which is administered via injection into the tumor site or subarachnoid space, in treating children and young adults with recurrent medulloblastoma or AT/RT.
To learn more about this trial, visit clinicaltrials.gov
Charity Partners: Ty Louis Campbell Foundation